21 -2 (88) 2026 - Navruzova R.S., Yusufjonova M.K. - EARLY BIOMARKERS OF PREECLAMPSIA: ANALYSIS OF ANGIOGENIC AND ANTI-ANGIOGENIC FACTORS

EARLY BIOMARKERS OF PREECLAMPSIA: ANALYSIS OF ANGIOGENIC AND ANTI-ANGIOGENIC FACTORS

Navruzova R.S. - Tashkent State Medical University

Yusufjonova M.K. - Tashkent State Medical University

Navruzova Sh.B. - Tashkent State Medical University

Resume

In preeclampsia, an imbalance of angiogenesis factors is observed. Pro-angiogenic factors such as placental growth factor (PlGF) and vascular endothelial growth factor receptor-2 (VEGFR2) are essential for normal placental development, while anti-angiogenic factors — soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) — disrupt vascular integrity and contribute to endothelial dysfunction. Changes in these biomarkers have been detected in women with preeclampsia even before the onset of clinical symptoms.

Key words: Preeclampsia, hypertension, pregnancy.

First page

103

Last page

106

For citation:Navruzova R.S., Yusufjonova M.K., Navruzova Sh.B. - EARLY BIOMARKERS OF PREECLAMPSIA: ANALYSIS OF ANGIOGENIC AND ANTI-ANGIOGENIC FACTORS//New Day in Medicine 2(88)2026 103-106 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

1. Робертс Дж. М., Купер Д. В. Патогенез и генетика преэклампсии. Lancet 2001;357:53–6. https://doi.org/10.1016/s0140-6736(00)03577-7 .Поиск в Google ScholarPubMed
2. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:5:1122-1131. https://doi.org/10.1097/01.aog.0000437382.03963.88
3. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. //J Obstet Gynaecol Can. 2014;36:5:416-441. https://doi.org/10.1016/S1701-2163(15)30588-0
4. Jhee JH, Lee S, Park Y, Lee SE, Kim YA, Kang SW, Kwon JY, Park JT. Prediction model development of late-onset preeclampsia using machine learning-based methods. PLoS One. 2019;14:8:e0221202. https://doi.org/10.1371/journal.pone.0221202
5. Постон, Л., Раймейкерс, М.Т. Окислительный стресс трофобласта, антиоксиданты и исход беременностиобзор. Placenta 2004;25:72-8 https://doi.org/10.1016/j.placenta.2004.01.003 .Поиск в Google ScholarPubMed
6. Портелли, М., Барон, Б. Клинические проявления преэклампсии и диагностическая ценность белков и продуктов их метилирования в качестве биомаркеров у беременных женщин с преэклампсией и их новорожденных. //J Pregnancy 2018;28:2632637. https://doi.org/10.1155/2018/2632637 .Поиск в Google ScholarPubMed PubMed Central
7. O'Gorman, N, Wright, D, Syngelaki, A, Akolekar, R, Wright, A, Poon, LC, et al.. Модель конкурирующих рисков при скрининге преэклампсии по материнским факторам и биомаркерам на 11–13 неделе беременности. Am J Obstet Gynecol 2016;214:103.e1–12. https://doi.org/10.1016/j.ajog.2015.08.034 .Поиск в Google ScholarPubMed
8. Cnossen JS, ter Riet G, Mol, BW, van der Post JA, Leeflang MM, Meads CA, et al.. Достаточно ли хороши тесты для прогнозирования преэклампсии, чтобы сделать скрининг эффективным? Обзор обзоров и критических оценок. Acta Obstet Gynecol Scand 2009;88:758–65. https://doi.org/10.1080/00016340903008953 .Поиск в Google ScholarPubMed
9. Шахид Р., Бари М.Ф., Хуссейн М. Сывороточные биомаркеры для прогнозирования и диагностики преэклампсии: метаанализ. //J Taibah Univ Med Sci 2021;17:14–27. https://doi.org/10.1016/j.jtumed.2021.07.003 .Поиск в Google ScholarPubMed PubMed Central

   file

   download